Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Jacobson Pharma's share price for the quarter that ended in Sep. 2024 was HK$0.62. Jacobson Pharma's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 1,986 Mil. Therefore, Jacobson Pharma's market cap for the quarter that ended in Sep. 2024 was HK$1,231 Mil.
Jacobson Pharma's quarterly market cap
declined
from Sep. 2023 (HK$1,301 Mil) to Mar. 2024 (HK$1,168 Mil) but then
increased
from Mar. 2024 (HK$1,168 Mil) to Sep. 2024 (HK$1,231 Mil).
Jacobson Pharma's annual market cap
increased
from Mar. 2022 (HK$889 Mil) to Mar. 2023 (HK$1,321 Mil) but then
declined
from Mar. 2023 (HK$1,321 Mil) to Mar. 2024 (HK$1,168 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Jacobson Pharma's Enterprise Value for Today is HK$2,631 Mil.
Jacobson Pharma Market Cap Historical Data
The historical data trend for Jacobson Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Jacobson Pharma's Market Cap
For the Drug Manufacturers - Specialty & Generic subindustry, Jacobson Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jacobson Pharma's Market Cap Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jacobson Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Jacobson Pharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Jacobson Pharma's Market Cap for the fiscal year that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jacobson Pharma (HKSE:02633) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Jacobson Pharma Market Cap Related Terms
Thank you for viewing the detailed overview of Jacobson Pharma's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Jacobson Pharma Corp Ltd is an investment holding company. It is principally engaged in the development, production, marketing, and sale of generic drugs. The company's operating segment includes Generic drugs; Branded healthcare, Wholesale, and retail The generic drugs segment develops, manufactures, and distributes a host of off-patent medicines for various therapeutic use. It generates maximum revenue from the Generic drugs segment. Geographically, it derives a majority of its revenue from Hong Kong and also has a presence in Mainland China, Macau, Singapore, and Other Countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02633 has been successfully added to your 